当前位置: X-MOL 学术Hepatology › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Monocarboxylate transporter 4 inhibition potentiates hepatocellular carcinoma immunotherapy through enhancing T cell infiltration and immune attack
Hepatology ( IF 12.9 ) Pub Date : 2022-01-19 , DOI: 10.1002/hep.32348
Yuan Fang 1 , Weiren Liu 1 , Zheng Tang 1 , Xiang Ji 2 , Yufu Zhou 1, 3 , Shushu Song 1, 4 , Mengxin Tian 1, 5 , Chenyang Tao 1 , Run Huang 1 , Guiqi Zhu 1 , Xifei Jiang 1 , Jun Gao 1 , Weifeng Qu 1 , Han Wang 1 , Peiyun Zhou 1 , Xiaoling Wu 1 , Lei Jin 1 , Haixiang Sun 1 , Zhenbin Ding 1 , Yuanfei Peng 1 , Shimin Zhao 6 , Jian Zhou 1 , Jia Fan 1 , Wei Xu 7 , Yinghong Shi 1
Affiliation  

Monocarboxylate transporter (MCT) 4 is a high-affinity lactate transporter that is primarily involved in the maintenance of intracellular pH homeostasis and highly expressed in different tumors. However, the role of MCT4 in modulating immune responses against HCC remains unknown.

中文翻译:


单羧酸转运蛋白 4 抑制通过增强 T 细胞浸润和免疫攻击来增强肝细胞癌免疫治疗



单羧酸转运蛋白 (MCT) 4 是一种高亲和力的乳酸转运蛋白,主要参与维持细胞内 pH 稳态,并在不同肿瘤中高表达。然而,MCT4 在调节 HCC 免疫反应中的作用仍不清楚。
更新日期:2022-02-10
down
wechat
bug